Open Actively Recruiting

STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors

About

Brief Summary

This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 1

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Selected Inclusion Criteria:

Selected Exclusion Criteria:

Join this Trial

Share:
Study Stats
Protocol No.
22-001830
Category
Cervical Cancer
Colorectal Cancer
Esophageal Cancer
Head and Neck Cancer
Kidney Cancer
Lung Cancer
Melanoma (Skin Cancer)
Ovarian Cancer
Prostate Cancer
Stomach Cancer
Uterine/Endometrial Cancer
Contact
Tina Tieu
Location
  • UCLA Alhambra
  • UCLA Burbank
  • UCLA Irvine
  • UCLA Pasadena
  • UCLA Porter Ranch
  • UCLA San Luis Obispo
  • UCLA Santa Clarita
  • UCLA Santa Monica
  • UCLA Westlake Village
For Providers
NCT No.
NCT05098132
For detailed technical eligibility, visit ClinicalTrials.gov.